The treatment, molnupiravir, cuts the rate of hospitalisation and death by 50% in a trial of mild-to-moderately ill patients who had at least one risk factor for the disease, according to data released.
The treatment, molnupiravir, cuts the rate of hospitalisation and death by 50% in a trial of mild-to-moderately ill patients who had at least one risk factor for the disease, according to data released.
+6012 275 0035
Daily top news delivered to your inbox FREE. Subscribe to enjoy privilege.